Next Article in Journal
Plasma and Tissue Specific miRNA Expression Pattern and Functional Analysis Associated to Colorectal Cancer Patients
Previous Article in Journal
Combination Treatment with Cold Physical Plasma and Pulsed Electric Fields Augments ROS Production and Cytotoxicity in Lymphoma
Open AccessReview

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

1
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan
2
Global Medical Oncology, Sanofi, Boston, MA 02142, USA
3
Gastrointestinal Tumors Service of the Medical Oncology Service, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, IOB, Barcelona 08035, Spain
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 844; https://doi.org/10.3390/cancers12040844
Received: 25 February 2020 / Revised: 26 March 2020 / Accepted: 27 March 2020 / Published: 31 March 2020
Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations. View Full-Text
Keywords: colorectal cancer; mCRC; VEGF inhibitor; anti-angiogenic therapy; aflibercept; clinical practice colorectal cancer; mCRC; VEGF inhibitor; anti-angiogenic therapy; aflibercept; clinical practice
Show Figures

Figure 1

MDPI and ACS Style

Muro, K.; Salinardi, T.; Singh, A.R.; Macarulla, T. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers 2020, 12, 844.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop